Alterations of DNA methylation in hematologic malignancies

Cancer Letters

Volumn 185, Issue 1, 2002, Pages 1-12

  Rush, Laura J ^a   Plass, Christoph ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Acute myeloid leukemia; Chemotherapeutics; Chronic lymphocytic leukemia; CpG island; Demethylation; DNA hypomethylation; DNA methylation; Epigenetics; Hematologic malignancy; Leukemia; Myelodysplastic syndrome; p15; p16

Indexed keywords

ANTINEOPLASTIC AGENT; DNA;

BLOOD DISEASE; CANCER; CANCER CELL; CELL ASSAY; CHEMOTHERAPY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; GENETIC TRANSCRIPTION; HUMAN; IN VIVO STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; SHORT SURVEY; SOLID TUMOR; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; REVIEW; TUMOR SUPPRESSOR GENE;

CELL TRANSFORMATION, NEOPLASTIC; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HEMATOLOGIC NEOPLASMS; HUMANS; PROMOTER REGIONS (GENETICS);

EID: 0037044560     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00288-4     Document Type: Review

References (101)

1. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model
2. The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia (letter)
3. CpG-rich islands and the function of DNA methylation
4. CpG islands in vertebrate genomes
5. Comprehensive analysis of CpG islands in human chromosomes 21 and 22
6. DNA methylation from embryo to adult
7. DNA methylation and genomic imprinting
8. Tissue and site-specific methylation correlates with expression of the mouse lactoferrin gene
9. Tissue-specific differences in DNA methylation in various mammals
10. Aging and DNA methylation in colorectal mucosa and cancer
11. DNMT1 binds HDAC2 and a new co-repressor, DMAP1 to form a complex at replication foci
12. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases
13. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells
14. Methylation matters
15. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics
16. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis
17. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers
18. The 5-methylcytosine content of DNA from human tumors
19. Reduced genomic 5-methylcytosine content in human colonic neoplasia
20. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription
21. Cell cycle-specific reactivation of an inactive X-chromosome locus by 5-azadeoxycytidine
22. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
23. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer
24. High sensitivity mapping of methylated cytosines
25. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
26. A genomic scanning method for higher organisms using restriction sites as landmarks
27. Restriction landmark genomic scanning for DNA methylation in cancer: Past, present, and future applications
28. DNA methylation analysis: A review of current methodologies
29. Analysis of in vivo methylation
30. Global and gene-specific methylation patterns in cancer: Aspects of tumor biology and clinical potential
31. Cytosine methylation changes during normal hematopoiesis and in acute myeloid leukemia
32. Kappa chain monoallelic demethylation and the establishment of allelic exclusion
33. DNA methylation and chromatin structure regulate PU.1 expression
34. Lineage-specific methylation of the c-fms gene in blood cells and macrophages
35. Cell lineage specificity in G-CSF receptor gene methylation
36. T cell differentiation: A mechanistic view
37. Distinct methylation of the interferon gamma (IFN-gamma) and interleukin 3 (IL-3) genes in newly activated primary CD8+ T lymphocytes: Regional IFN-gamma promoter demethylation and mRNA expression are heritable in CD44(high)CD8+ T cells
38. Inactivation of misselected CD8 T cells by CD8 gene methylation and cell death
39. Analysis of human peripheral blood T cells and single-cell-derived T cell clones uncovers extensive clonal CpG island methylation heterogeneity throughout the genome
40. Dynamic DNA methylation change in the CpG island region of p15 during human myeloid development
41. P15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing
42. Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia
43. 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia
44. Imprinting of insulin-like growth factor 2 is modulated during hematopoiesis
45. Loss of genomic imprinting of insulin-like growth factor 2 is strongly associated with cellular proliferation in normal hematopoietic cells
46. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia
47. Increased DNA methyltransferase expression in leukaemia
48. Methylation profiling in acute myeloid leukemia
49. Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci
50. The short arm of chromosome 11 is a "hot spot" for hypermethylation in human neoplasia
51. Selective variegated methylation of the p15 CpG island in acute myeloid leukemia
52. KG-1 and KG-1a model the p15 CpG island methylation observed in acute myeloid leukemia patients
53. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies
54. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms
55. Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia
56. Hypermethylation of E-cadherin in leukemia
57. E-cadherin expression is silenced by 5′ CpG island methylation in acute leukemia
58. HIC1 hypermethylation is a late event in hematopoietic neoplasms
59. Cancer-specific region of hypermethylation identified within the HIC1 putative tumour suppressor gene in acute myeloid leukaemia
60. Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; Involvement of the WIT-1 gene
61. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor
62. Chronic myelogenous leukemia
63. Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemia
64. Increasing methylation of the calcitonin gene during disease progression in sequential samples from CML patients
65. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia
66. Aberrant methylation of the major breakpoint cluster region in chronic myeloid leukemia
67. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes
68. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: It can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation
69. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation
70. Loss of p73 gene expression in lymphoid leukemia cell lines is associated with hypermethylation
71. CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia
72. Hypermethylation of the M27beta (DXS255) locus in chronic B-cell leukaemia
73. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma
74. Specific patterns of gene methylation in natural killer cell lymphomas: P73 is consistently involved
75. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies
76. Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas
77. The diagnositc significance of Myf-3 hypermethylation in malignant lymphoproliferative disorders
78. P16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies
79. P16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance
80. Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia
81. Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma
82. Loss of imprinting in disease progression in chronic myelogenous leukemia
83. Loss of imprinting of human insulin-like growth factor II gene, IGF2, in acute myeloid leukemia
84. Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer
85. Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer
86. Hypermethylation of the imprinted NNAT locus occurs frequently in pediatric acute leukemia
87. DNA methylation, imprinting and cancer
88. TCL1 is activated by chromosomal rearrangement or by hypomethylation
89. Promoter demethylation accompanies reactivation of the HOX11 proto-oncogene in leukemia
90. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance
91. Hypomethylation of ornithine decarboxylase gene and erb-A1 oncogene in human chronic lymphatic leukemia
92. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia
93. Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential
94. Genomic hypomethylation in human chronic lymphocytic leukemia
95. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: Clinical results and possible mechanisms of action
96. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients
97. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine
98. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report
99. Technology evaluation: MG-98, MethylGene
100. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns
101. Methylation-specific oligonucleotide microarray: A new potential for high-throughput methylation analysis